2seventy bio, Inc.
TSVT | $4.85 -4.15% 330K
|
(0.0% 1d) (12.7% 1m) (-43.0% 1y) (0.0% 2d) (4.1% 3d) (0.4% 7d) (-3.91% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 248,858,990
https://www.2seventybio.com
Sec Filling | Patents | 2022 employees
Its name, 2seventy bio, reflects why 2seventy bio does what 2seventy bio does - TIME. Cancer rips time away and its goal is to work at the maximum speed of translating human thought into action – 270 miles per hour — to give the people 2seventy bio serve more time. 2seventy bio is building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, 2seventy bio’s applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Its research and development is focused on delivering therapies that are designed with the goal to "think" smarter and faster than the disease. Importantly, 2seventy bio remains focused on accomplishing these goals by staying genuine and authentic to its "why" and keeping its people and culture top of mind every day.
treatment cancer t-cell
add to watch list Paper trade email alert is off
Press-releases
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: 2.27%
H: 8.4%
C: -0.99%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -0.32%
H: 1.67%
C: 0.04%
fda therapy
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Published: 2024-02-27 (Crawled : 15:30) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: 0.0%
H: 8.64%
C: 8.36%
NVS | News | $92.61 -0.51% 430K
|
Health Technology
|
| O: -0.15%
H: 0.31%
C: 0.06%
BLBD | $34.2 -0.06% 110K
|
Producer Manufacturing
|
| O: 1.02%
H: 1.29%
C: 1.17%
ALVR | $0.75 -0.91% 230K
|
Health Technology
|
| O: -1.42%
H: 7.9%
C: 3.52%
ADAP | $0.9089 -7.91% 740K
|
Health Technology
|
| O: 3.05%
H: 5.92%
C: 1.18%
pdufa commercial
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.85 -4.15% 330K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $900.22 -0.11% 150K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $146.09 0.53% 59K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Published: 2024-01-30 (Crawled : 12:00) - globenewswire.com
TSVT | $4.85 -4.15% 330K
|
|
| O: 11.17%
H: 12.63%
C: 3.35%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
REGN | $900.22 -0.11% 150K
|
Health Technology
|
| O: 0.02%
H: 0.44%
C: 0.39%
cell acquisition preclinical
2seventy bio Announces New Strategic Path Forward
Published: 2024-01-30 (Crawled : 13:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: 11.17%
H: 12.63%
C: 3.35%
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
REGN | $900.22 -0.11% 150K
|
Health Technology
|
| O: 0.02%
H: 0.44%
C: 0.39%
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: -4.02%
H: 9.35%
C: 4.84%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
therapy
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
Published: 2023-12-11 (Crawled : 14:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: -2.9%
H: 7.64%
C: 7.31%
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Published: 2023-11-20 (Crawled : 13:00) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: -11.74%
H: 1.06%
C: -7.45%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -4.05%
H: 2.85%
C: 0.25%
fda review update therapy
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
Published: 2023-11-10 (Crawled : 13:30) - biospace.com/
TSVT | $4.85 -4.15% 330K
|
|
| O: 2.65%
H: 0.0%
C: -6.03%
report financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Last 48 Hours Insiders Buying
TPL P 3 | $592.6 1.31% 22K
|
Miscellaneous
|
15:00
RELL | $10.24 3.85% 36K
|
Electronic Technology
|
13:30
IZEA | $2.53 16K
|
Technology Services
|
00:00
RKT P 383 | $11.735 3.12% 640K
|
Finance
|
22:30
CTRN P 18090 | $23.035 2.97% 16K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 44K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.07 -0.58% 840K
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10